ArticleCancer immunology, immunotherapy : CII2025
Identification of two distinct uveal melanoma subtypes based on the immune cell infiltration of the primary tumour.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUveal melanoma (UM) is the most common intraocular malignancy, with poor prognosis in metastatic cases and limited response to conventional therapies. Despite advances in genetic stratification, the immunological landscape of primary UM remains poorly understood.
methodsSecondary data generation of single-cell RNA sequencing (scRNA-seq) of primary class 1 and class 2 (loss of BAP1) UM tumours and flow cytometric analysis of 8 primary UM tumour biopsies were used to characterize the tumour microenvironment, cellular composition, tumour-immune cell interactions, and stromal marker expression associated with tumour progression and immune infiltration.
resultsscRNA-seq analysis revealed 16 distinct cell clusters, including melanocytes, T cells, macrophages, and stromal cells. Class 2 tumours contained unique melanocyte subpopulations exhibiting chromosome 8 copy number variations and enriched in hypoxia, PI3K-Akt, and MAPK signalling pathways. Ligand-receptor analysis identified extensive interactions between these aggressive melanocytes and pericytes/macrophages. Flow cytometric analysis confirmed two distinct immune infiltrate profiles: low-infiltrate tumours dominated by CD14⁺ cells, and high-infiltrate tumours with CD8⁺ memory-like T cells expressing PD-1 and CD27. Stromal marker analysis revealed elevated expression of CD81 and NGFR in immune-excluded tumours, implicating them in metastatic potential.
conclusionsOur study reveals cellular and immunological heterogeneity within primary UM tumours. The identification of immunologically distinct tumour types, along with aggressive melanocyte subpopulations and stromal interactions, provides insight into UM pathogenesis and supports stratified immunotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.